Evaluation Of The Diamine Oxidase Supplementation Effect In Patients With Insomnia Symptoms

Inclusion Criteria: * Older than 18 years * With the ability to understand and sign informed consent reviewed and approved by the Grupo Hospitalario Quironsalud-Catalunya. * That refer one or more symptoms of insomnia, these being: Difficulty initiating sleep, Difficulty maintaining sleep, Waking up early with inability to go back to sleep. * Who are carriers, either heterozygous or homozygous, of at least one of the following 4 SNPs associated with a reduction in the enzymatic activity of DAO or a decreased transcriptional activity of it: c.47C\>T (rs10156191), c.995C\>T (rs1049742), c.1990C\>G (rs1049793), c.-691G\>T (rs2052129). * With the ability to attend the foreseen face-to-face and telephonic study visits. * With the ability to intake the product under study * Explicit agreement on study participation by reading, understanding, and signing the informed consent reviewed and approved by the Grupo Hospitalario Quironsalud-Catalunya Exclusion Criteria: * Insomnia symptoms referred by patients that might be explained by other co-morbid sleep disorders, e.g., narcolepsy, circadian rhythm disturbances, parasomnia, etc. * Taking DAO supplementation less than 1 month prior to the start of the study. * Following a diet low in histamine less than 1 month prior to the start of the study. * Volunteers with allergies to some of the ingredients of the product under study.